

Webcast: Food and Drug Administration Developments: Key Updates and Compliance

Webcasts | October 22, 2025

Join our lawyers for a recorded in-depth discussion of recent developments at the U.S. Food and Drug Administration, including the FDA's crackdown on direct-to-consumer drug advertising and the impact of the Make America Healthy Again initiative, and their implications for the food, drug, device, and cosmetics industries. Our panel of attorneys provide practical insights and strategies for navigating emerging FDA policy, as well as regulatory and enforcement trends.

MCLE CREDIT INFORMATION: This program has been approved for credit in accordance with the requirements of the New York State Continuing Legal Education Board for a maximum of 1.5 credit hours, of which 1.5 credit hours may be applied toward the areas of professional practice requirement. This course is approved for transitional/non-transitional credit. Gibson, Dunn & Crutcher LLP certifies that this activity has been approved for MCLE credit by the State Bar of California in the amount of 1.5 hours. Gibson, Dunn & Crutcher LLP is authorized by the Solicitors Regulation Authority to provide in-house CPD training. This program is approved for CPD credit in the amount of 1.5 hours. Regulated by the Solicitors Regulation Authority (Number 324652). Neither the Connecticut Judicial Branch nor the Commission on Minimum Continuing Legal Education approve or accredit CLE providers or activities. It is the opinion of this provider that this activity qualifies for up to 1.5 hours toward your annual CLE requirement in Connecticut, including 0 hour(s) of ethics/professionalism. Application for approval is pending with the Colorado, Illinois, Texas, Virginia, and Washington State Bars.

Related People

[Jonathan M. Phillips](#)

[Gustav W. Eyler](#)

[Katlin McKelvie](#)

[John D.W. Partridge](#)

PANELISTS: **Jonathan Phillips** is a partner in Gibson Dunn's Washington, D.C. office and co-chairs the firm's FDA & Health Care Practice. His practice centers on FDA and health care enforcement, compliance, and litigation — including False Claims Act, Anti-Kickback, and regulatory defense work for pharmaceutical, medical device, and health-services clients. Prior to joining Gibson Dunn Jonathan served as a Trial Attorney in the Civil Division, Fraud Section of the U.S. Department of Justice where his work included handling a variety of health care enforcement cases. **Gustav Eyler** is a partner in Gibson Dunn's Washington, D.C. office and co-chairs the firm's FDA & Health Care and Consumer Protection Practice Groups. Leveraging years of experience as Director of the U.S. DOJ Consumer Protection Branch — where he led enforcement actions involving drugs, medical devices, food, deceptive marketing, and public health statutes — he defends clients in government investigations and counsels on the design and implementation of compliance programs. **Katlin McKelvie** is a partner in Gibson Dunn's Washington, D.C. office and co-chairs the firm's FDA & Health Care Practice. With over twenty years of experience in food and drug law, including as Deputy General Counsel at the Department of Health and Human Services (HHS), senior staff on the Senate HELP Committee, and various roles at FDA, she advises clients on regulatory, enforcement, legislative, and compliance strategies across FDA-regulated product categories. **John Partridge** is a partner in Gibson Dunn's Washington, D.C. office and co-chairs the firm's FDA & Health Care Practice. He specializes in white-collar defense, government and internal investigations, and complex litigation for life sciences and health care clients and brings deep experience defending corporations in enforcement actions under the False Claims Act, Anti-Kickback Statute, FCPA, and the Federal Food, Drug, and Cosmetic Act. © 2025

GIBSON DUNN

Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. Attorney Advertising: These materials were prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and circumstances may vary, and prior results do not guarantee a similar outcome.

Related Capabilities

[FDA and Health Care](#)